Confronto

Eloralintide vs. Survodutide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

2179963-22-7

Peso molecolare

nessun dato

4727 g/mol

Emivita

nessun dato

168 h

Sequenza

nessun dato

modifiziertes 29-Aminosäuren-Peptid mit Fettsäureseitenkette

Meccanismo d'azione

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Eloralintide	Survodutide
Germania	Non approvato	Non approvato
JP	—	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Eloralintide and Survodutide?: Eloralintide is classified as "Metabolico", while Survodutide is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Survodutide?: The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Survodutide in Germany and the United States?: Germania: Eloralintide — Non approvato, Survodutide — Non approvato. Stati Uniti: Eloralintide — Non approvato, Survodutide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Survodutide

Germania

Non approvato

—

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Eloralintide and Survodutide?

Eloralintide is classified as "Metabolico", while Survodutide is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Survodutide?

The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Survodutide in Germany and the United States?

Germania: Eloralintide — Non approvato, Survodutide — Non approvato. Stati Uniti: Eloralintide — Non approvato, Survodutide — Non approvato. These are factual summaries with source and review date on the individual pages.